Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
The British Snack Co makes quirky and original British snacks. The company's award-winning flavours and unique ranges of craft popcorn, crisps, and pork snacks have sold over 8 million bags to date. It aims to be a contender in the £3.2 billion UK snacks market. The company's products are stocked across major retailers like Waitrose, Ocado's, Morrisons, Borough Box, and Amazon, to name a few. Its craft pork scratching product, Awfully Posh, was the first pork snack ever to win a Great Taste Award. The company has been working with buyers in the hospitality industry to create joint marketing plans for after lockdown to rapidly grow its Out Of Home (OOH) sales. It will use 50% of the investment to grow its staff, 37.5% towards trade marketing, and 12.5% for New Product Development (NPD).
days to go:
Expired
investment:
£382,495
Hagley West is an online watch company co-owned by cricketing legend, Chris Gayle. The brand has more than 50,000 followers on Social Media and has already sold its products in 39 different countries. To eliminate high barriers constructed by big brand markups and sales agents, Hagley West has developed a strategy to deliver direct to the consumer. Hagley West aims at increasing its presence to billions of global cricket fans with growth plans focused in the Asian market. With the proceeds, the company will accelerate its core business, develop new ranges, and expand into new markets.
days to go:
Expired
investment:
£353,540
Hoptroff TTaaS® software is a hassle-free compliance solution for financial services under MIFID II and CAT regulations. Traceable Time as a Service (TTaaS®) ensures that timestamp records of computer transactions are accurate to the microsecond, making online transactions trustworthy, reducing fraud, regulatory risk and the cost of business for Financial Services and Media. Hoptroff is building their presence in the US – the largest potential market worth $30bn. They are fundraising with the goals to invest in PoC trials for the growing pipeline of potential global customers introduced by their partners, transitioning from annual up-front fees to monthly payments with BTR and invest in launching IP Media service.
days to go:
Expired
investment:
£865,000
Solent Automation specialises in developing, deploying and supporting automation robots to perform and tackle common manual labour-intensive tasks in factories. To solve the 'pick-and-place' challenges in an industrial setup, these robots are created with proven reliable components coupled with proprietary software to solve 'pick-and-place' challenges in an industrial environment. Two of the company's noteworthy products are 'SOLPAL 8' and 'SOLPACK 1XP, both are equipped with an all-in-one gripping tool, and can handle 16 boxes per minute and 60 packs per minute, respectively. Backed by a team of experts from manufacturing and robotics, Solent Automation provides on-site installation, training, and remote support for its products. There is also a rent-to-buy option through a 3rd party finance company. With the investment, the company aims at providing more robotic equipment most needed in factories focused on labour-intensive work functions.
days to go:
Expired
investment:
£76,000
